Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Harmony Biosciences Holdings, Inc. (HRMY) vs SELLAS Life Sciences Group, Inc. (SLS)

Harmony Biosciences Holdings, Inc. and SELLAS Life Sciences Group, Inc. are both Biotechnology companies. Harmony Biosciences Holdings, Inc. and SELLAS Life Sciences Group, Inc. are of similar size ($2.4B and $2.4B). SELLAS Life Sciences Group, Inc. has negative trailing earnings, so its P/E is not meaningful; Harmony Biosciences Holdings, Inc. trades at 13.2×. Harmony Biosciences Holdings, Inc. has the higher net margin (18.9% vs 0.00%) and the higher return on invested capital (29.7% vs 0.00%). Across the 16 metrics below, Harmony Biosciences Holdings, Inc. leads on 13 and SELLAS Life Sciences Group, Inc. on 3.

Valuation

Metric HRMY SLS Biotechnology median
P/E 13.18 n/m 7.88
P/S 2.49 209.18 11.47
P/B 2.39 15.96 2.52
Price to free cash flow 7.59 n/m 21.16
EV/EBITDA 7.35 n/m 0.74
EV/Sales 1.95 196.06 10.73
Earnings yield 7.59% (1.81%) (28.84%)
Free cash flow yield 13.17% (1.75%) (23.03%)

Profitability

Metric HRMY SLS Biotechnology median
Gross margin 75.42% 0.00% 65.16%
Operating margin 24.03% 0.00% 0.00%
Net margin 18.88% 0.00% 0.00%
Free cash flow margin 36.99% 0.00% 0.00%
Return on equity 20.46% (39.63%) (57.72%)
Return on assets 14.61% (36.54%) (49.22%)
Return on invested capital 29.70% 0.00% 0.00%

Growth

Metric HRMY SLS Biotechnology median
Revenue growth (TTM) 24.25% — 5.64%
EPS growth (last fiscal year) 7.97% 50.00% —
Revenue growth, 5-year CAGR 40.30% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric HRMY SLS Biotechnology median
Debt to equity 0.15 0.00 0.00
Current ratio 3.48 18.83 4.73
Net debt to EBITDA (2.63) 2.54 0.96

Dividend

Metric HRMY SLS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric HRMY SLS Biotechnology median
Market cap 2.40b 2.37b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack